BlackRock’s Anixa Biosciences ANIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $559K | Buy |
199,755
+29,652
| +17% | +$82.5K | ﹤0.01% | 4546 |
|
|
2026
Q1 | $439K | Buy |
170,103
+6,120
| +4% | +$18.1K | ﹤0.01% | 4561 |
|
|
2025
Q4 | $512K | Buy |
163,983
+2,961
| +2% | +$12.1K | ﹤0.01% | 4478 |
|
|
2025
Q3 | $531K | Buy |
161,022
+1,554
| +1% | +$4.92K | ﹤0.01% | 4442 |
|
|
2025
Q2 | $526K | Sell |
159,468
-35,955
| -18% | -$103K | ﹤0.01% | 4427 |
|
|
2025
Q1 | $559K | Buy |
195,423
+12,391
| +7% | +$35.4K | ﹤0.01% | 4369 |
|
|
2024
Q4 | $425K | Buy |
183,032
+20,691
| +13% | +$64.3K | ﹤0.01% | 4452 |
|
|
2024
Q3 | $511K | Buy |
162,341
+1,925
| +1% | +$5.92K | ﹤0.01% | 4319 |
|
|
2024
Q2 | $355K | Buy |
160,416
+5,754
| +4% | +$16.3K | ﹤0.01% | 4427 |
|
|
2024
Q1 | $483K | Sell |
154,662
-2,135
| -1% | -$8.51K | ﹤0.01% | 4378 |
|
|
2023
Q4 | $608K | Sell |
156,797
-4,769
| -3% | -$16.1K | ﹤0.01% | 4384 |
|
|
2023
Q3 | $528K | Sell |
161,566
-90,004
| -36% | -$315K | ﹤0.01% | 4408 |
|
|
2023
Q2 | $805K | Buy |
251,570
+4,210
| +2% | +$16.2K | ﹤0.01% | 4340 |
|
|
2023
Q1 | $1.06M | Sell |
247,360
-46,859
| -16% | -$205K | ﹤0.01% | 4319 |
|
|
2022
Q4 | $1.25M | Sell |
294,219
-3,294
| -1% | -$15.8K | ﹤0.01% | 4337 |
|
|
2022
Q3 | $1.46M | Buy |
297,513
+195,603
| +192% | +$793K | ﹤0.01% | 4341 |
|
|
2022
Q2 | $311K | Sell |
101,910
-54
| -0.1% | -$170 | ﹤0.01% | 4912 |
|
|
2022
Q1 | $279K | Sell |
101,964
-3,204
| -3% | -$9.4K | ﹤0.01% | 5031 |
|
|
2021
Q4 | $312K | Sell |
105,168
-5,124
| -5% | -$20.7K | ﹤0.01% | 5001 |
|
|
2021
Q3 | $525K | Sell |
110,292
-7,737
| -7% | -$34.9K | ﹤0.01% | 4743 |
|
|
2021
Q2 | $458K | Buy |
118,029
+15,809
| +15% | +$67.3K | ﹤0.01% | 4714 |
|
|
2021
Q1 | $478K | Buy |
102,220
+8,278
| +9% | +$39.6K | ﹤0.01% | 4616 |
|
|
2020
Q4 | $289K | Buy |
93,942
+6,964
| +8% | +$17.5K | ﹤0.01% | 4422 |
|
|
2020
Q3 | $212K | Sell |
86,978
-1,201
| -1% | -$3.1K | ﹤0.01% | 4398 |
|
|
2020
Q2 | $271K | Buy |
88,179
+8,198
| +10% | +$17K | ﹤0.01% | 4316 |
|
|
2020
Q1 | $128K | Sell |
79,981
-1,117
| -1% | -$3.27K | ﹤0.01% | 4312 |
|
|
2019
Q4 | $266K | Sell |
81,098
-4,891
| -6% | -$17.9K | ﹤0.01% | 4279 |
|
|
2019
Q3 | $344K | Buy |
85,989
+6,315
| +8% | +$26.4K | ﹤0.01% | 4235 |
|
|
2019
Q2 | $289K | Buy |
79,674
+29,823
| +60% | +$126K | ﹤0.01% | 4293 |
|
|
2019
Q1 | $225K | Sell |
49,851
-2,545
| -5% | -$12.1K | ﹤0.01% | 4225 |
|
|
2018
Q4 | $206K | Buy |
52,396
+263
| +0.5% | +$1.13K | ﹤0.01% | 4226 |
|
|
2018
Q3 | $242K | Buy |
52,133
+6,565
| +14% | +$24.7K | ﹤0.01% | 4272 |
|
|
2018
Q2 | $139K | Buy |
45,568
+40,748
| +845% | +$151K | ﹤0.01% | 4394 |
|
|
2018
Q1 | $19K | Hold |
4,820
| – | – | ﹤0.01% | 4569 |
|
|
2017
Q4 | $11K | Hold |
4,820
| – | – | ﹤0.01% | 4624 |
|
|
2017
Q3 | $13K | Hold |
4,820
| – | – | ﹤0.01% | 4649 |
|
|
2017
Q2 | $6K | Hold |
4,820
| – | – | ﹤0.01% | 4770 |
|
|
2017
Q1 | $14K | Buy |
+4,820
| New | +$20.7K | ﹤0.01% | 4666 |
|
Other funds holding ANIX
LNWTC
DADC
GCP
BlackRock's ANIX Position: Q2 2026 in Review
BlackRock increased its Anixa Biosciences (ANIX) stake by 17% in Q2 2026, buying an estimated $82.5K and bringing the position to 199,755 shares worth $559K. The position accounts for ﹤0.01% of the portfolio, ranked #4546.
BlackRock first reported a position in ANIX in Q1 2017 and has held it in 38 quarters since. The position peaked at $1.46M in Q3 2022. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.
- BlackRock held 199,755 shares of Anixa Biosciences worth $559K as of Q2 2026.
- BlackRock bought 29,652 Anixa Biosciences shares in Q2 2026, an estimated $82.5K.
- Anixa Biosciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4546 holding.
- BlackRock first reported a position in Anixa Biosciences in Q1 2017 and has held it in 38 quarters since.
- BlackRock's Anixa Biosciences position peaked at $1.46M in Q3 2022.
- 62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.